ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Regeneron Pharmaceuticals, Bayer and Sanofi side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

Regeneron Pharmaceuticals×Bayer×Sanofi×Three at a time for now; Pro will compare up to ten.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

Regeneron PharmaceuticalsBayerSanofi
studies on the registry4131,6942,425
open to participants now8360105
phase 3 studies under way381161
reach primary completion within a year303566
programswith a study of their own in two years432181+12 named only

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseRegeneron PharmaceuticalsBayerSanofi
Phase 1

Regeneron Pharmaceuticals: 8 of its 43 programs at phase 1

  1. REGN9533phase 1
  2. ALN-SNCAphase 1
  3. REGN17235phase 1
  4. REGN20423phase 1
  5. REGN20934phase 1

and 3 more — sign in to see them all

19%
19%28%
Phase 2

Regeneron Pharmaceuticals: 16 of its 43 programs at phase 2

  1. ALN-PNPphase 2
  2. vonsetamigphase 2
  3. ALN-ANG3phase 2
  4. olsutamigphase 2
  5. ubamatamabphase 2

and 11 more — sign in to see them all

37%

Bayer: 8 of its 21 programs at phase 2

  1. AB-1005phase 2
  2. WRN Inhibitor RO7589831phase 2
  3. nurandociguatphase 2
  4. BAY 3401016phase 2
  5. BAY 3670549phase 2

and 3 more — sign in to see them all

38%

Sanofi: 25 of its 81 programs at phase 2

  1. brivekimigphase 2
  2. Acne mRNA vaccinephase 2
  3. Daxokafusp Alfaphase 2
  4. RSV+HMPV vaccinephase 2
  5. BLU-808phase 2

and 20 more — sign in to see them all

31%
Phase 3

Regeneron Pharmaceuticals: 15 of its 43 programs at phase 3

  1. cemiplimabphase 3
  2. cenvacibartphase 3
  3. fianlimabphase 3
  4. odronextamabphase 3
  5. amrecibartphase 3

and 10 more — sign in to see them all

35%

Bayer: 4 of its 21 programs at phase 3

  1. elinzanetantphase 3
  2. sevabertinibphase 3
  3. bemdaneprocelphase 3
  4. aficamtenphase 3
19%

Sanofi: 22 of its 81 programs at phase 3

  1. rilzabrutinibphase 3
  2. frexalimabphase 3
  3. Pneumococcal 21-Valent Conjugate Vaccinephase 3
  4. lunsekimigphase 3
  5. duvakitugphase 3

and 17 more — sign in to see them all

27%
Approved, new studies

Regeneron Pharmaceuticals: 4 of its 43 programs at approved, new studies

  1. linvoseltamabapproved, new study
  2. pozelimabapproved, new study
  3. dupilumabapproved, new study
  4. alirocumabapproved, new study
9%

Bayer: 5 of its 21 programs at approved, new studies

  1. finerenoneapproved, new study
  2. darolutamideapproved, new study
  3. Aspirinapproved, new study
  4. acoramidisapproved, new study
  5. Levonorgestrelapproved, new study
24%

Sanofi: 11 of its 81 programs at approved, new studies

  1. dupilumabapproved, new study
  2. belumosudilapproved, new study
  3. sarilumabapproved, new study
  4. fitusiranapproved, new study
  5. Avapritinibapproved, new study

and 6 more — sign in to see them all

14%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
Regeneron Pharmaceuticals14 readouts · 4 phase 3·

Regeneron Pharmaceuticals, Dec ’26: 2 programs whose next study reaches primary completion

  1. ALN-ANG3phase 2 · Dec 4 · NCT06452771
  2. alirocumabapproved, new study · Dec 29 · NCT07477704

Regeneron Pharmaceuticals, Jan ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. fianlimabphase 3 · Jan 15 · NCT05608291

Regeneron Pharmaceuticals, Feb ’27: 4 programs whose next study reaches primary completion

  1. REGN22044phase 1 · Feb 8 · NCT07526116
  2. amrecibartphase 3 · Feb 9 · NCT07175428
  3. cenvacibartphase 3 · Feb 9 · NCT07175428
  4. REGN20934phase 1 · Feb 22 · NCT07594093

Regeneron Pharmaceuticals, Mar ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. cemiplimabphase 3 · Mar 22 · NCT06246916

Regeneron Pharmaceuticals, Apr ’27: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. REGN9533phase 1 · Apr 2 · NCT07759167
  2. dupilumabapproved, new study · Apr 24 · NCT06572228
·

Regeneron Pharmaceuticals, Jun ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. mibavademabphase 3 · Jun 18 · NCT07220772
·

Regeneron Pharmaceuticals, Aug ’27: 3 programs whose next study reaches primary completion

  1. ALN-PNPphase 2 · Aug 10 · NCT05648214
  2. ALN-CIDEBphase 3 · Aug 17 · NCT06836609
  3. linvoseltamabapproved, new study · Aug 31 · NCT06369467
··
Bayer10 readouts · 4 phase 3·

Bayer, Dec ’26: 1 program whose next study reaches primary completion

  1. BAY 3389934phase 1 · Dec 25 · NCT06854640

Bayer, Jan ’27: 1 program whose next study reaches primary completion

  1. elinzanetantphase 3 · Jan 22 · NCT07762287
·

Bayer, Mar ’27: 1 program whose next study reaches primary completion

  1. Aspirinapproved, new study · Mar 10 · NCT07652723

Bayer, Apr ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. finerenoneapproved, new study · Apr 10 · NCT05196035

Bayer, May ’27: 2 programs whose next study reaches primary completion

  1. nurandociguatphase 2 · May 7 · NCT07431294
  2. WRN Inhibitor RO7589831phase 2 · May 31 · NCT06004245
·

Bayer, Jul ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. darolutamideapproved, new study · Jul 30 · NCT05794906

Bayer, Aug ’27: 1 program whose next study reaches primary completion

  1. RAS/PI3K-alpha Inhibitor VVD-159642phase 1 · Aug 1 · NCT06804824

Bayer, Sep ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. acoramidisapproved, new study · Sep 17 · NCT07298044

Bayer, Oct ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. sevabertinibphase 3 · Oct 28 · NCT06452277
Sanofi30 readouts · 10 phase 3

Sanofi, Nov ’26: 3 programs whose next study reaches primary completion, 3 in phase 3

  1. rilzabrutinibphase 3 · Nov 25 · NCT07216079
  2. NVX-CoV2373 adjuvated lipid nanoparticleapproved, new study · Nov 26 · NCT07861542
  3. Measles, combinations with mumps and rubella, live attenuatedphase 3 · Nov 28 · NCT07103148

Sanofi, Dec ’26: 5 programs whose next study reaches primary completion, 1 in phase 3

  1. Pandemic flu H5 HA mRNA SD2 vaccinephase 2 · Dec 1 · NCT06907511
  2. Pneumococcal 21-Valent Conjugate Vaccinephase 3 · Dec 1 · NCT06838000
  3. brivekimigphase 2 · Dec 17 · NCT06958536
  4. frexalimabphase 3 · Dec 23 · NCT06500702
  5. BLU-808phase 2 · Dec 31 · NCT06931405

Sanofi, Jan ’27: 5 programs whose next study reaches primary completion, 1 in phase 3

  1. efanesoctocog alfaapproved, new study · Jan 15 · NCT04644575
  2. RSV+HMPV vaccinephase 2 · Jan 18 · NCT06686654
  3. Daxokafusp Alfaphase 2 · Jan 19 · NCT05584670
  4. belumosudilapproved, new study · Jan 26 · NCT07726914
  5. rF1V-1018phase 2 · Jan 29 · NCT07207408

Sanofi, Feb ’27: 2 programs whose next study reaches primary completion, 2 in phase 3

  1. dupilumabapproved, new study · Feb 7 · NCT07905547
  2. itepekimabphase 3 · Feb 17 · NCT07424144

Sanofi, Mar ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. fitusiranapproved, new study · Mar 25 · NCT05662319

Sanofi, Apr ’27: 6 programs whose next study reaches primary completion

  1. H5 Flu IMP 2phase 1 · Apr 4 · NCT07516418
  2. Inosine Monophosphatephase 1 · Apr 4 · NCT07516418
  3. RSV IMP 4phase 1 · Apr 4 · NCT07516418
  4. RSV IMP 5phase 1 · Apr 4 · NCT07516418
  5. RSV IMP 6phase 1 · Apr 4 · NCT07516418

and 1 more — sign in to see them all

Sanofi, May ’27: 1 program whose next study reaches primary completion

  1. SAR402663phase 2 · May 18 · NCT06660667

Sanofi, Jun ’27: 2 programs whose next study reaches primary completion

  1. lunsekimigphase 3 · Jun 21 · NCT06676319
  2. Avapritinibapproved, new study · Jun 23 · NCT03731260

Sanofi, Jul ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. riliprubartphase 3 · Jul 9 · NCT06290141

Sanofi, Aug ’27: 1 program whose next study reaches primary completion

  1. SAR448632phase 1 · Aug 15 · NCT07944885

Sanofi, Sep ’27: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. zetrukibartphase 2 · Sep 22 · NCT07225569
  2. amlitelimabphase 3 · Sep 30 · NCT06241118

Sanofi, Oct ’27: 1 program whose next study reaches primary completion

  1. SAR446597phase 2 · Oct 13 · NCT07215234
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 20, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

Regeneron Pharmaceuticals

New programs 5

  • REGN9220phase 2 · first study · Oct 14 · Lymphoma, Large B-Cell, Diffuse
  • REGN13089phase 2 · first study · Oct 2 · Carcinoma, Renal Cell
  • REGN24493phase 1 · first study · Sep 30 · Graves Disease
  • REGN21353phase 2 · first study · Sep 23 · Prostatic Neoplasms
  • ALN-6457phase 2 · first study · Sep 16 · Dementia

Reached a new phase 2

Study stopped 0

None

Primary completion later 6

Bayer

New programs 0

None

Reached a new phase 1

Study stopped 0

None

Primary completion later 2

Sanofi

New programs 6

Reached a new phase 1

Study stopped 4

  • balinatunfibphase 2 · terminated Oct 22 · none of its studies left running“Business decision” · NCT07222189
  • balinatunfibphase 2 · terminated Oct 21 · none of its studies left running“Business decision” · NCT06867094
  • balinatunfibphase 2 · terminated Oct 13 · none of its studies left running“Business decision.” · NCT06637631
  • amlitelimabphase 2 · terminated Oct 2“Sponsor decision; the decision is not related to any safety concern.” · NCT06033833

Primary completion later 2

Where they overlap

Conditions where at least two of them have programs: 25 in all, the first 12 here. A program counts in each condition its studies name most.

ConditionRegeneron PharmaceuticalsBayerSanofi
Carcinoma, Non-Small-Cell Lungall three · compare here

Regeneron Pharmaceuticals in Carcinoma, Non-Small-Cell Lung: 3 programs

  1. cemiplimabphase 3
  2. fianlimabphase 3
  3. ubamatamabphase 2

Their studies: Regeneron Pharmaceuticals’ studies of Carcinoma, Non-Small-Cell Lung in search

Bayer in Carcinoma, Non-Small-Cell Lung: 2 programs

  1. sevabertinibphase 3
  2. PRMT5 Inhibitor BAY 3713372phase 2

Their studies: Bayer’s studies of Carcinoma, Non-Small-Cell Lung in search

Sanofi in Carcinoma, Non-Small-Cell Lung: 2 programs

  1. Tadalafilphase 3
  2. Pan-KRAS Inhibitor BLU-924phase 2

Their studies: Sanofi’s studies of Carcinoma, Non-Small-Cell Lung in search

Diabetes Mellitus, Type 2all three · compare here

Regeneron Pharmaceuticals in Diabetes Mellitus, Type 2: 1 program

  1. olatorepatidephase 3

Their studies: Regeneron Pharmaceuticals’ studies of Diabetes Mellitus, Type 2 in search

Bayer in Diabetes Mellitus, Type 2: 2 programs

  1. finerenoneapproved, new study
  2. Levonorgestrelapproved, new study

Their studies: Bayer’s studies of Diabetes Mellitus, Type 2 in search

Sanofi in Diabetes Mellitus, Type 2: 1 program

  1. iGlarLixi (insulin glargine/lixisenatide)approved, new study

Their studies: Sanofi’s studies of Diabetes Mellitus, Type 2 in search

Parkinson Diseaseall three · compare here

Regeneron Pharmaceuticals in Parkinson Disease: 1 program

  1. ALN-SNCAphase 1

Their studies: Regeneron Pharmaceuticals’ studies of Parkinson Disease in search

Bayer in Parkinson Disease: 2 programs

  1. bemdaneprocelphase 3
  2. AB-1005phase 2

Their studies: Bayer’s studies of Parkinson Disease in search

Sanofi in Parkinson Disease: 1 program

  1. Biological Productsphase 1

Their studies: Sanofi’s studies of Parkinson Disease in search

Dermatitis, Atopic2 of 3 · compare here

Regeneron Pharmaceuticals in Dermatitis, Atopic: 2 programs

  1. REGN20423phase 1
  2. dupilumabapproved, new study

Their studies: Regeneron Pharmaceuticals’ studies of Dermatitis, Atopic in search

–

Sanofi in Dermatitis, Atopic: 5 programs

  1. lunsekimigphase 3
  2. amlitelimabphase 3
  3. itepekimabphase 3
  4. Dupilumab coformulated with berahyaluronidase alfaphase 3
  5. dupilumabapproved, new study

Their studies: Sanofi’s studies of Dermatitis, Atopic in search

Asthma2 of 3 · compare here

Regeneron Pharmaceuticals in Asthma: 1 program

  1. dupilumabapproved, new study

Their studies: Regeneron Pharmaceuticals’ studies of Asthma in search

–

Sanofi in Asthma: 5 programs

  1. lunsekimigphase 3
  2. duvakitugphase 3
  3. amlitelimabphase 3
  4. itepekimabphase 3
  5. dupilumabapproved, new study

Their studies: Sanofi’s studies of Asthma in search

Carcinoma, Renal Cell2 of 3 · compare here

Regeneron Pharmaceuticals in Carcinoma, Renal Cell: 3 programs

  1. olsutamigphase 2
  2. Anti-PSMA/Anti-4-1BB Bispecific Antibody REGN15505phase 2
  3. REGN13089phase 2

Their studies: Regeneron Pharmaceuticals’ studies of Carcinoma, Renal Cell in search

–

Sanofi in Carcinoma, Renal Cell: 1 program

  1. Biological Productsphase 1

Their studies: Sanofi’s studies of Carcinoma, Renal Cell in search

Multiple Myeloma2 of 3 · compare here

Regeneron Pharmaceuticals in Multiple Myeloma: 3 programs

  1. vonsetamigphase 2
  2. REGN17372phase 2
  3. linvoseltamabapproved, new study

Their studies: Regeneron Pharmaceuticals’ studies of Multiple Myeloma in search

–

Sanofi in Multiple Myeloma: 1 program

  1. Anti-GPRC5D Monoclonal Antibody SAR446523phase 1

Their studies: Sanofi’s studies of Multiple Myeloma in search

Nasal Polyps2 of 3 · compare here

Regeneron Pharmaceuticals in Nasal Polyps: 1 program

  1. dupilumabapproved, new study

Their studies: Regeneron Pharmaceuticals’ studies of Nasal Polyps in search

–

Sanofi in Nasal Polyps: 3 programs

  1. lunsekimigphase 3
  2. itepekimabphase 3
  3. dupilumabapproved, new study

Their studies: Sanofi’s studies of Nasal Polyps in search

Pulmonary Disease, Chronic Obstructive2 of 3 · compare here

Regeneron Pharmaceuticals in Pulmonary Disease, Chronic Obstructive: 1 program

  1. dupilumabapproved, new study

Their studies: Regeneron Pharmaceuticals’ studies of Pulmonary Disease, Chronic Obstructive in search

–

Sanofi in Pulmonary Disease, Chronic Obstructive: 3 programs

  1. lunsekimigphase 3
  2. itepekimabphase 3
  3. dupilumabapproved, new study

Their studies: Sanofi’s studies of Pulmonary Disease, Chronic Obstructive in search

Atrial Fibrillation2 of 3 · compare here

Regeneron Pharmaceuticals in Atrial Fibrillation: 2 programs

  1. cenvacibartphase 3
  2. amrecibartphase 3

Their studies: Regeneron Pharmaceuticals’ studies of Atrial Fibrillation in search

Bayer in Atrial Fibrillation: 1 program

  1. BAY 3670549phase 2

Their studies: Bayer’s studies of Atrial Fibrillation in search

–
Colorectal Neoplasms2 of 3 · compare here–

Bayer in Colorectal Neoplasms: 2 programs

  1. sevabertinibphase 3
  2. WRN Inhibitor RO7589831phase 2

Their studies: Bayer’s studies of Colorectal Neoplasms in search

Sanofi in Colorectal Neoplasms: 1 program

  1. tusamitamab sonditecanphase 1

Their studies: Sanofi’s studies of Colorectal Neoplasms in search

Coronary Artery Disease2 of 3 · compare here

Regeneron Pharmaceuticals in Coronary Artery Disease: 1 program

  1. alirocumabapproved, new study

Their studies: Regeneron Pharmaceuticals’ studies of Coronary Artery Disease in search

Bayer in Coronary Artery Disease: 2 programs

  1. nurandociguatphase 2
  2. Aspirinapproved, new study

Their studies: Bayer’s studies of Coronary Artery Disease in search

–

Show all 25

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

A target, or a pathogen for a vaccine, known for: Regeneron Pharmaceuticals 17 of 43 · Bayer 13 of 21 · Sanofi 54 of 81 programs (39 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.
  • Programs a company names but has not registered are counted apart (Sanofi: 12).